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Abstract 
 
Hypoxic pulmonary vasoconstriction is correlated with pulmonary vascular 
remodelling.  The hypoxia-inducible transcription factors (HIFs), HIF-1α and 
HIF-2α are known to contribute to the process of hypoxic pulmonary vascular 
remodelling; however, the specific role of pulmonary endothelial HIF 
expression in this process, and in the physiological process of 
vasoconstriction in response to hypoxia, remains unclear. Here we show that 
pulmonary endothelial HIF-2α is a critical regulator of hypoxia-induced 
pulmonary arterial hypertension (PAH). The rise in right ventricular systolic 
pressure (RVSP) normally observed following chronic hypoxic exposure was 
absent in mice with pulmonary endothelial HIF-2α deletion. The RVSP of mice 
lacking HIF-2α in pulmonary endothelium after exposure to hypoxia was not 
significantly different from normoxic wild type (WT) mice and much lower than 
the RVSP values seen in WT littermate controls and mice with pulmonary 
endothelial deletion of HIF-1α exposed to hypoxia. Endothelial HIF-2α 
deletion also protected mice from hypoxia remodelling.  Pulmonary 
endothelial deletion of arginase-1, a downstream target of HIF-2α, likewise 
attenuated many of the pathophysiological symptoms associated with HPH. 
We propose a mechanism whereby chronic hypoxia enhances HIF-2α 
stability, which causes increased arginase expression and dysregulates 
normal vascular NO homeostasis.  These data offer new insight into the role 
of pulmonary endothelial HIF-2α in regulating the pulmonary vascular 
response to hypoxia. 
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Significance Statement 
The expression of hypoxia inducible factor-(HIF)2a in pulmonary endothelium 
of mice influences pulmonary vascular resistance and development of hypoxic 
pulmonary hypertension (PH) via an arginase-1 dependent mechanism.  The 
HIF-2a:arginase-1 axis influences the homeostatic regulation of nitric oxide 
synthesis in the lung.  Impaired generation of this vasoactive agent 
contributes to the initial development and vascular remodelling process of PH. 
\body 
Introduction 
Alveolar hypoxia affects vascular flow in the pulmonary vascular bed via an 
immediate vasoconstrictor response (hypoxic pulmonary vasoconstriction, or 
HPV) (1).  This reduces perfusion of regions of the lung with lowered levels of 
air flow (2). In conditions including chronic obstructive pulmonary disease (3), 
idiopathic pulmonary fibrosis (4), and at high altitude (5), HPV probably 
contributes to persistent increases in pulmonary arterial pressures.  This in 
turn is correlated with reduced plasticity of the vascular bed, sustained 
pulmonary vascular remodelling and, ultimately, debilitating right ventricular 
hypertrophy and failure(2). 
 
The hypoxia inducible factors (HIFs) are transcription factors and key 
regulators of the molecular response to hypoxia. The targets of HIFs include 
genes controlling vascularization, cellular proliferation, migration, and 
metabolism(6-11). A well-characterized animal model of hypoxia-induced 
pulmonary hypertension involves exposure to chronic hypoxia (CH), typically 
10-12% inspired oxygen. This results in extensive vascular remodelling, 
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marked pulmonary hypertension and right ventricular hypertrophy over a 
period of a few weeks. Exposure to CH in rodents results in vasoconstriction 
and a pattern of vascular remodelling that is reminiscent of humans with 
hypoxia-associated pulmonary hypertension (12, 13). 
 
Mice that are hemizygous for either of the HIF isoforms, HIF-1α (14) or HIF-
2α (15), have been shown to have attenuated pulmonary vascular remodelling 
following experimental CH. Conditional deletion of HIF-1α in smooth muscle 
also ameliorates the degree of remodelling in CH(16). The mechanisms by 
which HIF acts in pulmonary vascular remodelling are not fully defined; in 
particular, the role played by the endothelium in this process is not well 
understood.  Here, we delete the HIF isoforms and one of their targets, the 
Arg1 gene, specifically in the pulmonary endothelium (17), and show that 
expression of the HIFα transcription factors in pulmonary endothelial cells is 
an essential aspect of the hypoxic response of the lung. 
 
 
Results 
Deletion of HIFα isoforms in pulmonary endothelium  
Genetically manipulated mouse strains with conditional alleles of either the 
HIF-1α or -2α isoforms (18, 19) were crossed to mouse strains expressing the 
cre recombinase enzyme under the control of the pulmonary endothelium-
specific Alk1- or L1 promoter (L1cre) (17).  To determine tissue specificity of 
this transgene, we analysed the cre activity of adult L1cre mice by crossing 
with a ROSA26Sortm9(CAG-tdTomato) reporter strain. As shown, lung vasculature 
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was easily identifiable.  Minimal expression of tdTomato was detectable in the 
endothelium of other tissues (Supplemental Figure 1A). Deletion efficiency 
was assessed and deletion was greater than 80% (Supplemental Figure 1B), 
with little or no detectable deletion in other tissues. 
 
HIF-2α deletion in the pulmonary endothelium prevents hypoxia-induced 
pulmonary hypertension 
Wild type (WT) and pulmonary endothelial HIF-α deleted mice were exposed 
to normoxic or hypoxic (10% O2) normobaric atmospheres for 21 days.  
Pulmonary hypertension was assessed through measurement of right 
ventricular systolic pressures (RVSPs) (Figure 1A). RVSP in L1cre-HIF-2α 
mice (18.9±1.0 mmHg, n=11) under normoxic conditions were significantly 
lower than littermate controls (22.4±1.1 mmHg, n=9, p=0.03) mice. However 
RVSP from normoxic L1cre-HIF-1α mice (24.7±1.7 mmHg, n=6) did not differ 
from WT controls (Figure 1A).   
The RVSPs of L1cre-HIF-2α mice following hypoxic exposure (26.1±1.6 
mmHg, n=7) were not significantly different from those of untreated WT mice 
(22.48±1.19, n=9) and were much lower than the elevated values seen in WT 
littermate controls (41.9±1.8 mmHg, n=12, p<0.0001) and L1cre-HIF-1α mice 
(36.25±2.37mmHg, n=7, p<0.005)(Figure 1A). 
The ratio of right ventricular weights to those of the left ventricle plus septum 
(RV/LS+S), an indicator of right ventricular hypertrophy, was likewise 
significantly higher in wild-type (0.316±0.01, n=8, p<0.0001) and L1cre-HIF-
1α (0.323±0.02, n=8, p<0.001) mice exposed to hypoxia compared to the 
ratios found in L1cre-HIF-2α (0.209±0.008, n=8) mice (Figure 1B). WT and 
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mutant mice reacted to hypoxia normally in other respects (Supplemental 
Figures 2A-2C). 
 
Pulmonary endothelial HIF-2α is essential for vascular remodelling 
Medial thickening of pulmonary vessels was calculated.  Both WT littermates 
and L1cre-HIF-1α mice showed significantly increased medial thickness 
following hypoxic conditioning (Figure 1C).  In comparison, hypoxic L1cre-
HIF-2α mice showed a large relative reduction in medial thickness relative to 
WT animals.  Normoxic animals showed no changes in vessel structure 
(Supplemental Figure 3).  
Serial lung sections were immunostained to mark endothelial cells.  Lungs 
from wild-type and L1cre-HIF-1α mice had typical tissue remodelling following 
chronic hypoxia (Figure 1D), with an increase in α-SMA associated with 
pulmonary arteries (Figure 1E). However, little to no remodelling was 
observed in lung sections from L1cre-HIF-2α mice (Figure 1F).  Lung sections  
showed increases in elastin in both WT controls and L1cre-HIF-1α mice, but 
only minimal staining in the L1cre-HIF-2α mice (Figure 1D) (20).  Collagen 
was also significantly higher in hypoxia-conditioned WT and L1cre-HIF-1α 
mice relative to L1cre-HIF-2α mice (Supplemental Figure 4A). Pulmonary 
endothelial deletion of HIF-2α reduced smooth muscle cell coverage after 
hypoxic exposure (Figure 1F).  In comparison, both WT littermate control and 
L1cre-HIF-1α mice developed full and partial rings of α-SMA positive cells 
around vessels in hypoxia-conditioned animals (Figure 1F). 
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Reduced Arginase expression in HIF2α mutant mice 
Previous work from our laboratory and others has demonstrated that the two 
HIFα isoforms act to control NO homeostasis during hypoxia.  This occurs 
through HIF1α regulation of the NOS2/iNOS gene, and HIF-2α regulation of 
the Arg-1 and Arg-2 genes (21-25). The enzyme Arg-2 in particular has been 
implicated in reducing airway NO and promoting remodelling and collagen 
deposition in PAH patients (26, 27).   We found that hypoxic up-regulation of 
arg-1 and -2 was reduced in hypoxia-conditioned isolated murine primary 
pulmonary endothelial cells (Supplemental Figure 5A) and whole lung 
samples from L1cre-HIF-2α mice, relative to WT littermate controls following 
hypoxic conditioning (Figure 2A).   
Consistent with these data, we found that plasma NO(X) concentrations were 
significantly reduced in HIF-1α mice and elevated in HIF-2α mutant mice 
when compared to WT control mice (Figure 2B); this was mirrored in an 
increase in NO metabolites detected in whole lung extracts of hypoxically 
treated animals (Figure 2C). There was also an increase in exhaled NO 
detected in HIF-2α mutant mice (Figure 2D). Although several recent studies 
have highlighted the role of endothelin-1 (ET-1) in pulmonary hypertension 
and indicated its regulation by the HIF pathway, purified lung endothelial cells 
showed little change in ET-1 expression in this model (Supplemental Figures 
5B-5D). There was a significant increase in PDGFβ expression in WT mice 
during the acute hypoxic phase (days1-3) before levels return to near baseline 
at the chronic phase (day 21). However there appears to be little separation 
between WT and L1cre-HIF2α mice (Supplemental Figure 6A-D). We further 
analyzed a number of stem cell markers known to be upregulated in PAH 
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(28).  We found enhanced whole lung gene expression of both Oct3-4 and 
nanog in WT when compared to L1cre-HIF2α mice (Supplemental Figure 6E-
H).  
 
Pulmonary endothelial arginase-1 deletion attenuates PAH 
We next sought to determine how the specific deletion of arginase-1 in the 
pulmonary endothelium influenced the development of PAH.  The increase in 
RVSP normally observed following chronic hypoxic challenge (for WT mice, 
41.7±0.8mm/Hg, n=7, p<0.0001) was significantly attenuated in mice with 
pulmonary endothelial arginase-1 deletion (31.2±1.0mmHg, n=7) (Figure 2E). 
Basal RVSPs in L1cre-arg1 mice under normoxia (23.0±0.7mmHg, n=6) were 
similar to those seen in littermate WT control mice (24.3±0.3mmHg, n=5).  
The ratio of right ventricular weight to left ventricle plus septum (RV/LS+S) 
was significantly higher in wild-type (0.39±0.01, n=6, p<0.001) when 
compared to L1cre-arg1 (0.33±0.01, n=9) mice, following chronic hypoxic 
exposure (Figure 2F); the animals otherwise responded normally to hypoxia 
(Supplemental Figure 7A). Wild type littermates showed significantly greater 
medial thickening (18.57%, n=15) when compared to L1cre-arg1 mice 
(14.35%, n=9) after exposure to chronic hypoxia (Figure 2G).  Collagen 
deposition around the bronchial associated vasculature was significantly 
higher in hypoxically conditioned WT control mice relative to L1cre-arg1 mice 
(Supplemental Figure 4B). 
L1cre-arg1 mice showed substantially less α-SMA associated with pulmonary 
arteries in close proximity to terminal bronchioles when compared to wild type 
controls (Supplemental Figure 7B). Staining for α-SMA was also substantially 
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reduced in the peripheral pulmonary vasculature of these mutants (Figure 2H-
I). Deletion of pulmonary endothelial arg-1 significantly elevated plasma NO(x) 
relative to the levels seen in plasma from wild type control mice (Figure 2J). 
 
Changes in acute response to hypoxia caused by loss of endothelial 
HIF-2α 
Hypoxia rapidly stimulates pulmonary vascular resistance (HPV), and 
increases the pressure needed to maintain normal output from the right 
ventricle of the heart.  We compared HPV in WT control and mutant animals 
by measuring right ventricular systolic pressures (RVSP), both immediately 
before and during hypoxic challenge (method shown in Figure 3A). L1cre-HIF-
2α mice have a lower resting RVSP (18.99±1.00mmHg, n=11) than WT 
control animals (22.47±1.19mmHg, n=9)(Figure 1A); nonetheless, the 
magnitude of pressure changes induced by hypoxia were still significantly 
lower in mice lacking pulmonary endothelial HIF-2α (3.10±0.60mmHg, n=13) 
relative to that seen in WT animals (5.45±0.76mmHg, n-13 p=0.023).  RVSP 
recorded from L1cre-HIF-1α (4.56±1.53mmHg, n=7) mice, however, did not 
significantly deviate from WT controls (Figure 3B) during acute hypoxic 
exposure.  Thus, acute pressure changes in the pulmonary circulation 
induced by hypoxia are significantly lower in animals that lack HIF-2α in the 
pulmonary endothelium. Baseline arterial saturations for L1cre-HIF-2α mice 
did not deviate from wild-type controls (Figure 3C).  However during the acute 
hypoxic challenge, there was a strong trend towards greater desaturation in 
the L1cre-HIF-2α when compared to WT mice (Figure 3C, p=0.06, n=7). 
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Whole-body plethysmography showed that resting ventilation rates in 
normoxia are similar in the HIFα mutant animals relative to WT controls (WT 
control 168±3.0 breaths per minute (BrPM), L1cre-HIF-1α 174±2.8 BrPM and 
L1cre-HIF-2α 170±2.7 BrPM)(Figure 3D). All mice responded to acute 
hypoxia by increasing ventilation rates. L1cre-HIF-1α and WT littermate 
control mice increased to 258 and 250 BrPM respectively for the initial 5 
minutes before reducing their ventilation rates to 187 and 174 BrPM during 
the first hour of exposure to hypoxia.  However, L1cre-HIF-2α mice increased 
respiratory rate to 308 BrPM, then reduced their ventilation rates to 233 BrPM 
in the same time period (Figure 3D). Of note, both tidal volume and peak 
inhalation/exhalation flow rates are comparable between the three groups 
(Supplemental Figure 8 A, B and C), indicating that there is no anatomic 
difference in pulmonary capacity.  The carotid bodies in all animals were 
histologically normal (Supplemental Figure 8D-H). 
 
Endothelial progenitor cells from human PAH patients have altered HIF-
2α-dependent arginase expression 
Blood outgrowth endothelial cells (BOECs) have been extensively used as a 
model for studying in-vitro endothelial function in vascular disorders (29, 30) 
with close functional and gene expression similarity to pulmonary artery 
endothelial cells(31). 
Previous work has shown enhanced expression and activity of Arg-2 in PAH 
patients (27, 32).  As shown here by Western blotting, no defect in hypoxia-
driven stability of HIF-1α and HIF-2α expression in these cells and confirm the 
normoxic over-expression at mRNA and protein and activity of Arg-2 in these 
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cells (Fig 4A and Supplemental Fig 9A and B).  Hypoxia further increases the 
expression of Arg-2 in these BOECs from PAH patients.  
BOEC’s from control volunteers produce significantly more NO than BOECs 
from PAH patients following 48 hours in culture (Supplemental Fig 9C).  NO 
production was restored to near that seen in control BOECs following 
arginase inhibition with S-(2-boronoethyl)-L-cysteine (BEC) (Supplemental Fig 
9C).  Short-hairpin (sh)RNA technology was employed to specifically knock-
down HIF-1α, HIF-2α, and Arg-2 in these BOECs.  These data show that 
knock-down of HIF-2α suppresses the expression of Arg-2 (Figure 4B) and 
decreases Arg-2 enzyme activity in these cells from patients with PAH (Figure 
4C). 
 
 
Discussion 
In this study, we have shown that the endothelial cell is a necessary element 
in the changes that result in PAH, and that the HIF isoform HIF-2α is in turn 
required for that endothelial response.  We also observed the down-regulated 
expression of arginase in isolated pulmonary endothelial cells and whole 
lungs from L1cre-HIF2a mice following chronic hypoxia, and demonstrate 
here that deletion of arginase-1 specifically in the pulmonary endothelium 
attenuated the development of hypoxic pulmonary hypertension.  Given the 
role of HIF-2α in regulating arginases specifically, this indicates that a key 
aspect of the function of HIF-2α in PAH is its regulation of arginase 
expression. 
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The HIF pathway was implicated in PH initially through demonstrations 
showing that mice hemizygous for HIF-1α or HIF-2α have diminished levels of 
pulmonary hypertension (15, 33); subsequent work was able to show that 
hemizygosity for HIF-1α resulted in changes in myocyte hypertrophy and 
polarization(14).  In contrast, hemizygosity of HIF-2α revealed that endothelial 
changes resulting in PAH were partially blocked when HIF-2α was 
diminished(15). Recent studies have also shown that PHD2 loss, which gives 
rise to increased HIF protein stability, promotes a HIF-2α-dependent increase 
in pulmonary hypertension(34, 35). These studies further demonstrate the 
importance of the HIF pathway in the etiology of PAH. 
 
The causal link between pulmonary hypertension and NO homeostasis has 
been extensively documented (26, 36), and this is reflected clinically in the 
finding that intrapulmonary nitrates, biochemical reaction products of NO in 
bronchoalveolar fluid, and exhaled NO are all diminished in human pulmonary 
hypertension (37, 38).  Interestingly, primary pulmonary endothelial cells 
isolated from PAH patients have substantially increased expression of arg-2 
(27), which would be predicted to decrease available L-arginine and reduce 
NOS-derived NO formation.  We have previously shown that both Arg1 and 
Arg2 are HIF-2α-dependent genes, and we show here that their expression in 
pulmonary endothelium is decreased in HIF-2α pulmonary endothelium 
mutants.  This should result in an increase in pulmonary endothelial NO, 
which itself has been shown to alleviate PAH experimentally (39).  Consistent 
with this hypothesis, genetic deletion of arg-1 resulted in a marked attenuation 
in the pathologies associated with PAH. Given a mechanistic link between 
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these findings and the etiology of PAH, future therapies to manipulate the 
control of NO homeostasis by the HIFα pathway should certainly be explored.  
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Methods 
Animals.  All animals were housed in an Association and Accreditation of 
Laboratory Animal Care International-approved facility.  All protocols and 
surgical procedures were approved by the local and national animal care 
committees. Targeted deletion of HIF-1α, HIF-2α and arginase-1 in pulmonary 
endothelial cells was created by crossing (C57Bl6/j) homozygous for the 
floxed allele in HIF-1α, HIF-2α or arginase-1 into a background of Cre 
recombinase expression drive by the L1 (alk-1) promoter kindly donate by Dr 
Paul Oh, Florida University.(17)   Mice characterized as wild type (WT) were 
in all cases littermates of respective mutant mice, homozygous for conditional 
alleles but without the cre recombinase transgene. 
 
Measurement of Right Ventricular Systolic Pressure (RVSP).  For 
induction of PAH due to chronic hypoxia, groups of male mice (8-12 weeks) 
were maintained in a normobaric hypoxic chamber (FiO2 10%) for up to 21 
days. Mice were weighed then anesthetised (isoflurane) and right-sided heart 
catheterisation through the right jugular using a pressure-volume loop 
catheter (Millar).(40-42)  Bloods were taken for haemodynamic assessment. 
 
Right Ventricular Hypertrophy.  To measure the extent of right ventricular 
hypertrophy (RVH), the heart was removed and the right ventricule (RV) free 
wall was dissected from the left ventricle plus septum (LV+S), and weighed 
separately.(43)  The degree of RVH was determined from the ratio RV/LV+S. 
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Tissue Preparation.  In all animals the left lung was fixed in situ in the 
distended state by the infusion of 0.8% agarose into the trachea, and then 
placed in 10% paraformaldehyde before paraffin embedding.  The right lung 
was frozen in liquid nitrogen for mRNA extraction. 
 
Pulmonary Vascular Morphometry.  Detailed methods in supplemental 
material and methods online. 
 
Haematological Analysis. Anti-coagulated blood was analysed using Vet 
abc haematology analyser (Horiba) according to the manufacturers 
instructions. 
 
Nitrite/Nitrate Analysis.  Blood samples were centrifuged to separate plasma 
and were passed through a column with a 10-kDa cut-off filter.  All samples 
were analysed for total NO(X) content using a NOA 280i (Siever, GE 
Healthcare) according to the manufacturers instructions. 
 
RNA Analysis. Detailed methods in supplemental material and methods 
online. 
 
Blood outgrowth endothelial cells (BOEC) isolation culture. 
BOECs have been extensively used as a model for studying in-vitro 
endothelial function in vascular disorders (29, 30) and we have previously 
demonstrated their close functional and gene expression similarity to 
pulmonary artery endothelial cells(31).  BOECs were isolated as previously 
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described (44).  BOECs were isolated from peripheral blood was taken from 
consenting healthy volunteers at the Addenbrooke;s University of Cambridge 
teaching Hospital NHS Foundation Trust, Cambridge, UK following a protocol 
approved by the Cambridge (UK) Research Ethics Committee 
(REF:11/EE/0297). Detailed methods in supplemental material methods 
online. 
 
Arginase activity assay 
BOECs were prepared in lysis buffer for an arginase activity assay as 
previously described (45).  Detailed methods in supplemental material and 
methods online. 
 
Carotid Body Histology.  Carotid body histology was performed as 
previously reported(46).  Carotid body volume and cell numbers were 
quantified on microscope images (Leica DM-RB) using ImageJ software.  
Detailed methods in supplemental material methods online. 
 
Whole Body Unrestrained Plethysmography. A single chamber 
plethysmograph (Data Science) was used in conjunction with a pressure 
transducer.  Non-anesthetized mice were randomly placed into the 
plethysmograph and allowed to acclimate, once acclimated to the chamber, 
the composition of the flow gas was switched from 21% O2 to 10% O2 using a 
PEGAS mixer (Columbus instruments).  Detailed methods in supplemental 
material and methods online. 
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Exhaled Nitric Oxide analysis 
Exhaled nitric oxide was measured non-invasively in non-anesthetised mice 
using a closed chamber system as previously described (47). Briefly, gas 
phase NO was measured by a chemiluminescence-based NO analyser 
sensitive to 0.1ppb NO (NOA 280i Sievers, Boulder CO). Detailed methods in 
supplemental material and methods online. 
 
Primary Lung endothelial cell isolation 
Primary endothelial cells were isolated and cultured from lungs of L1cre-
HIF2α and wt mice, as previously described(25). Detailed methods in 
supplemental material and methods online. 
 
Knockdown experiments. 
Human blood outgrowth endothelial cells derived from both control and PAH 
donors were transduced using lentiviral particles containing three different 
short hairpin RNAs (shRNAs) targeting human HIF-1α, HIF-2α, and Arg-2 
mRNA, respectively.  Detailed methods in supplemental material and methods 
online. 
 
Statistical Analysis. All data represents the mean (±SEM) of n separate 
experiments unless otherwise stated.  Difference between groups were 
assessed using t test unless otherwise stated.  A p value of <0.05 was 
considered significant. 
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Figure Legends 
 
Figure 1. Pulmonary endothelial HIF-2α contributes to chronic hypoxic pulmonary 
hypertension. (A) Scatter plot (mean ± SEM) of right ventricular systolic pressure 
(RVSP).  Wild-type (WT) and L1cre-HIFα mice were housed in normoxia (N) or 
chronic hypoxia (H) (WT (N) n=9 (H) n=12; L1cre-HIF-1α (N) n= 6 (H) n=7; L1cre-
HIF-2α (N) n=11 (H) n=7). (B) Right ventricular hypertrophy.  Scatter plot (mean ± 
SEM) show RV/LV+S weight ratio in mice exposed to normoxia (N) or chronic 
hypoxia (H) (WT (N) n=9 (H) n=12; L1cre-HIF-1α (N) n= 6 (H) n=7; L1cre-HIF-2α 
(N) n=11 (H) n=7).  (C and D) Airway remodelling in wild-type (WT) (n=15), L1cre-
HIF-1α (n=7) and L1cre-HIF-2α (n=7) post-chronic hypoxic challenge. (C) Scatter 
plot (mean ± SEM) of pulmonary vessel medial thickness.  Quantification of the 
intimal medial thickness achieved by staining lung sections with EVG. (D) 
Histological sections immunostained with α−smooth-muscle actin(α-SMA), von 
Willebrand factor(vWF), and Elastic van Gieson (EVG).  Representative 
photomicrographs (200µM bar) demonstrate lack of remodelling in L1cre-HIF-2α 
pulmonary arteries associated with terminal bronchi.  Loss of HIF-2α in pulmonary 
endothelial cells reduces the degree of muscularization of peripheral arteries.  (E) 
Stacked bar chart showing muscularization of peripheral pulmonary arteries in 
lung sections (blue bar = full muscle ring, green bar = partial muscle ring, yellow 
bar = no muscle ring) from wild-type (WT) (n=15), L1cre-HIF-1α (n=9) and L1cre-
HIF-2α (n=7) mice.  (F) Representative photomicrographs (100µM bar) 
immunostained for α-smooth muscle (arrows point to distal vessels). *P<0.05, 
**P<0.001, ***P<0.0001 
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Figure 2.  Endothelial deletion of HIF-2α maintains higher plasma nitrate levels.  
(A) qPCR analysis of arginase-I/-II, NOS2, and VEGF mRNA from whole lung 
samples of wild-type (WT) (open bar, n=7), L1cre-HIF-1α (blue bar, n=7) and 
L1cre-HIF-2α (red bar, n=6). (B) Total nitric oxide in plasma and (C) whole lung by 
the conversion of NO(X) to NO using a nitric oxide analyser (Siever).  Data shown 
as scatter plot with mean ± SEM from WT (n=7), L1cre-HIF-1α (n=7) and L1cre-
HIF-2α (n=6) post chronic hypoxia challenge.  Whole lung lysate analysis for 
NO(X) in normoxic (C) wt (open bar n=7), L1cre-HIF2α          n=7) L1cre-
Arg1 (green bar n=4) and following chronic hypoxia (10% O2 21-days), wt (white 
checker n=16) L1cre-HIF2α      checker     n=7) L1cre-Arg1 (green 
checker bar n=9).  Exhaled nitric oxide was measured non-invasively in non-
anesthetised mice in normoxia (D) gas phase NO was measured by a 
chemiluminescence-based NO analyser (Carrier gas baseline 1.7ppb dotted line).  
Data shown as bar graph with mean ± SEM for normoxic WT (n=13), and L1cre-
HIF-2α (n=8) and L1-Arg1(n=5).  Pulmonary endothelial deletion of Arg-1 
attenuates hypoxic pulmonary hypertensive phenotype.   (E) Scatter plot (mean ± 
SEM) shows the effect of pulmonary endothelial Arg-1 on right ventricular systolic 
pressure (RVSP).  Wild-type (WT) and L1cre-Arg1 mice were housed in normoxia 
(N) or chronic hypoxia (H) (WT (N) n=5 (H) n=7; L1cre-Arg1 (N) n= 6 (H) n=7. (F) 
Effect of pulmonary endothelial Arg-1 on right ventricular hypertrophy.  Scatter 
plot (mean ± SEM) show RV/LV+S weight ratio in mice exposed to normoxia (N) 
or chronic hypoxia (H) (WT (N) n=6 (H) n=6; L1cre-Arg1 (N) n= 7 (H) n=9. (G) 
Airway remodelling was determined in wild-type (WT) (n=8), L1cre-Arg1 (n=10).  
Quantification of the intimal medial thickness. (H) Stacked bar chart showing the 
degree of muscularization of peripheral pulmonary arteries in lung sections from 
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wild-type (WT) (n=5), L1cre-Arg1 (n=6) mice.  (I) Representative 
photomicrographs (100µM bar) immunostained for α-smooth muscle actin 
showing near and complete ring formation in peripheral vessel of WT mice when 
compared to L1cre-Arg1 mice. (J) Total nitric oxide was determined in the plasma 
by the conversion of NOx to NO using a nitric oxide analyser (Siever).  Data 
shown as scatter plot with mean ± SEM from WT (n=6), L1cre-Arg1 (n=8) post 
chronic hypoxia challenge *P<0.05, **P<0.001, ***P<0.0001. 
 
Figure 3. Acute hypoxic pulmonary vasoconstriction is significantly blunt in L1cre-
HIF-2α mutants. (A) Line diagram showing the time line and gas composition 
used to determine the acute hypoxic pulmonary vasoconstriction response. (B) 
Acute hypoxic pulmonary vasoconstriction was determined by measuring RVSP 
before and during acute hypoxic challenge (10% O2).  The delta between the two 
pressures was determined as the hypoxic vasoconstriction response.  Data shown 
in bar graph as mean ± SEM from wild-type (WT) (n=13) L1cre-HIF-1α (n=7) and 
L1cre-HIF-2α (n=13).  (C) Percentage arterial oxygen saturation was recorded 
during the acute hypoxic challenge.  Data recorded at 5 sec intervals mean ± 
SEM of wild-type (n=7) and L1cre-HIF-2α (n=7) (D) Ventilation rate in response to 
acute hypoxia was determined by whole-body plethysmography.  
Resting/normoxic ventilation was determined 60 minutes prior to acute hypoxic 
stimulus.  Data shown as mean breaths per minute ± SEM for WT (n=10) L1cre-
HIF-1α (n=5) and L1re-HIF-2α (n=6). *P<0.05 
 
 Figure 4. Analysis of human blood out-growth endothelial Cells (BOECs) as a 
model for studying in-vitro endothelial function in pulmonary arterial hypertension 
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(PAH).  (A) Western blot analysis of HIF1α and HIF2α stability and arginase-2 
expression in normoxia and 16hr post hypoxia.  Data shown in bar graph as a 
ratio of target gene to β-actin, mean ± SEM of control (closed bar n=3) and PAH 
(red bar n=4). (B) A lentiviral short-hairpin RNA strategy was employed to target 
HIF1α, HIF2α and Arg-2 expression.  Three shRNA were used to knock-down 
each gene of interest. A scramble-sh and GFP-tagged lentivirus and no-treatment 
were included as controls.  Data shown (mean ± SEM qPCR fold change 
compared to no-treatment control) for Arg-2 from control (closed bar, n=3) and 
PAH (red bar, n=3) 16hr post hypoxia.  (C) Cell lysates were analysed for 
arginase activity following the shRNA strategy to knock-down HIF1α, HIF2α and 
Arg-2.  Data shown as mean ± SD of urea produced corrected per mg of protein 
lysate for control (closed bar n=2) and PAH (red bar n=2).   *P<0.05, **P<0.001 
(control) *P<0.05, **P<0.001(PAH). 
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Supplemental Figure Legends 
 
Supplemental Figure 1. L1cre specificity for pulmonary endothelial cells.  
Representative photomicrographs from 3 independent mice (A) show bright-
field structure of frozen lung (cre- / cre+) heart (cre+), kidney (cre+) and liver 
(cre+) sections, immunohistochemistry staining red for podocalyxin 
(vasculature), green td-RFP (cre+ activity) and merged image. (B) L1cre 
deletion efficiency of HIF-2α in isolated pulmonary endothelial cells and other 
selected whole organs. Isolated endothelial data shown as single experiment 
from six pooled animals.   
 
Supplemental Figure 2.  Haematological and body weight response to 
chronic hypoxia, and a hypoxic time course of endothelial 
HIF1α    e    . (A) Red blood cell counts (RBC), haemoglobin (HGB) 
scores and (B) white cell counts (WBC) did not deviate between the groups 
(A) Data shown as scatter graph as mean ± SEM of RBC, HGB and WBC 
from normoxic (N) and chronic hypoxic (H) housed wild-type (WT) (n=9 and 
n=15) L1cre-HIF-1α (n=9 and n=8) and L1cre-HIF-2α (n=7 and n=8).  (C) Bar 
graph of mean ± SEM body weight, normoxic (N) and after chronic hypoxia 
(H) from WT (n=8), L1cre-HIF-1α (n=7) and L1cre-HIF-2α (n=8).  Deletion of 
endothelial HIF1α did not modulate the development of right ventricular 
hypertrophy (D) or the accumulation of red-blood cells (E) compared to wt 
control throughout the hypoxic time course of 7-14-21days.  Data shown as 
scatter graph as mean ± SEM of RV/LV+S and RBC counts for WT (n=5-17) 
and L1cre-HIF-1α (n=5-13). 
 
Supplemental Figure 3.  Histological sections from paraffin wax embedded 
lungs were immunostained for αSmooth-Muscle actin, von Willebrand factor, 
and stained for hematoxylin & eosin and Elastic van Gieson (EVG).  
Representative photomicrographs show no remodelling in normoxic housed 
L1cre-HIF-1α or L1cre-HIF-2α mice when compared to wild-type control. 
 
Supplemental Figure 4. Deletion of pulmonary endothelial HIF-2α or Arg-1 
decreases collagen deposition around arteries associated with terminal 
bronchus.  Histological lung sections were stained using Sirius red and then 
analysed by image J software.  Data shown as bar graph for (A) wild-type 
(WT) (open bar, n=7), L1cre-HIF-1α (blue bar, n=6) and L1cre-HIF-2α (red 
bar, n=7) and (B) wild-type (open bar, n=5) and L1cre-Arg-1 (green bar n=6) 
and representative photomicrographs show the degree of collagen deposition 
following chronic hypoxic challenge. **P<0.001 
 
 
Supplemental Figure 5.  Arginase and Endothelin-1 expression in isolated 
pulmonary endothelial cells and whole lung.  (A and B) QPCR data from a 
single experiment of six pool animals, pulmonary endothelial cells isolated 
from wild-type or L1cre-HIF-2α mice culture in normoxia or hypoxia for 24hrs. 
(C) QPCR analysis of ET-1 expression in whole lung tissue from wild-type 
(n=15), L1cre-HIF-1α (n=7) and L1cre-HIF-2α (n=6) mice following chronic 
hypoxic challenge.  (D) Acute hypoxic increase in plasma endothelin-1 was 
inhibited in the L1cre-HIF1α (n=4) and L1cre-HIF2α (n=4) mice when 
compared to wild-type (n=6). Plasma endothelin-1 was significantly lower in 
L1cre-HIF2α (n=8) compared to wt (n=8)following chronic hypoxic challenge 
Data bar shown as mean ± SEM.  (E) Exhaled nitric oxide was measured non-
invasively in non-anesthetised mice following chronic hypoxia, gas phase NO 
was measured by a chemiluminescence-based NO analyser.  Data shown as 
scatter graph with mean ± SEM WT (n=6), and L1cre-HIF-2α (n=6) and L1-
Arg1(n=5)*P<0.05. 
 
Supplemental Figure 6. Endothelial deletion of HIFα does not influence the 
hypoxic modulated expression of PDGFα / β or PDGF-receptor A/B.  QPCR 
data (fold change) for PDGFα / β and PDGF receptor A/B expression in whole 
lung from wt (n=8-16) (A and C) L1cre-HIF-1α (n=8) and (B and D) L1cre-HIF-
2α (n=8).  QPCR data (fold change) for stem cell markers nanog, oct3-4, klf4 
and sox2 are shown for wt (n=8) and L1re-HIF2α (n=8). Data shown over a 
hypoxic time course 0-1-3-21 days. *P<0.05. 
 
Supplemental Figure 7. Red blood cell counts (RBC), haemoglobin (HGB) 
did not deviate between the groups (A) Data shown as scatter graph as mean 
± SEM of RBC and HGB from normoxic (N) and chronic hypoxic (H) housed 
wild-type (WT) (n=6(N) and 4(H)) L1cre-Arg1 (n=6 (N) and n=9(H)) (B) 
Histological sections of lung were immunostained with α−smooth-muscle 
actin(α-SMA), von Willebrand factor(vWF), and Elastic van Gieson (EVG).  
Representative photomicrographs demonstrate the remarkable attenuation of 
remodelling in L1cre-Arg1 pulmonary arteries associated with terminal bronchi 
when compared to WT control 
 
Supplemental Figure 8. Pulmonary respiratory response to acute hypoxia. 
(A,B and C) Minute volume, tidal volume and flow rate in response to hypoxia 
were determined by whole-body plethysmography.  Data shown as mean ± 
SEM for wild-type (n=10), L1cre-HIF-1α (n=5) and L1cre-HIF-2α (n=6).  
Pulmonary endothelial HIF-2α does not influence carotid body development.  
(D and E) Representative photomicrographs showing immunostaining of TH+ 
cells in the carotid bifurcation of wild-type (WT) (n=5) and L1cre-HIF-2α (n=5).  
To facilitate comparison, the areas inside the rectangles are shown at a 
higher magnification.  ECA, external carotid artery; ICA, internal carotid artery; 
CB, carotid body; SCG, superior cervical ganglion. Scale bar 200µm and 
20µm respectively. Quantification of (F) CB TH+ cells, (G) carotid body 
volume, and (H) CB TH+ cells per area of tissue. 
 
Supplemental Figure 9.  Analysis of human Blood Out-growth Endothelial 
Cells (BOECs) for arginase-2 expression, activity and NO synthesis.  (A) 
qPCR analysis of arginase-2, data shown as mean ± SEM from control (open 
bar n=3) and PAH (red bar n=4), (B) arginase activity assay data shown as 
mean ± SEM from control (open bar n=4) ± arginase inhibitor (BEC)(black 
checker bar n=4) and PAH (red bar n=3) ± arginase inhibitor (BEC)(red and 
black checker), (C) NO analysis of whole cell lysates from BOECs cultured for 
48hr.  Data shown as mean ± SEM from control (open bar n=4) ± arginase 
inhibitor (BEC)(black checker bar n=4) and PAH (red bar n=3) ± arginase 
inhibitor (BEC)(red and black checker). 
A lentiviral short-hairpin RNA strategy was employed to target HIF1α, HIF2α 
and Arg-2.  Three different shRNA were used to knock-down each gene of 
interest, including a scramble-sh and GFP-tagged lentivirus and no-treatment 
were included as controls.  Data shown (mean ± SEM qPCR fold change 
compared to no-treatment control) for (A) HIF1α and (B) HIF2α from control 
(closed bar, n=3) and PAH (red bar, n=3) 16hr post hypoxia. **P<0.001 
(control) **P<0.001(PAH). 
 
  
Supplemental Methods 
 
 
Blood outgrowth endothelial cells (BOEC) isolation culture. 
BOECs have been extensively used as a model for studying in-vitro 
endothelial function in vascular disorders and we have previously 
demonstrated their close functional and gene expression similarity to 
pulmonary artery endothelial cells. 
Participants were previously diagnosed with pulmonary arterial hypertension 
or normal health volunteers.  Mononuclear cells were isolated from 60 ml of 
venous blood by Ficoll density gradient centrifugation and plated onto type 1 
rat tail collagen–coated (BD Biosciences, Bedford, MA) flasks in endothelial 
selective medium (EGM2; Lonza Biologics, Slough, UK) supplemented with 
10% ES-screened fetal calf serum and additional growth factors (EGM2 bullet 
kit; Lonza Biologics). BOECs appear after 2–3 weeks and were subsequently 
passaged when confluent.  Inhibition of arginase-2 activity, BOECs were 
culture with S-(2-boronoethyl)-L-cysteine (BEC) 24h before analysis. 
Arginase activity assay 
BOECs were prepared from cell lysate (50uL) added to 75uL of Tris-HCl 
(50mmol/L, pH 7.5) containing 10 mmol/L MnCl2.  Heat lysate to 55oC for 10 
min.  Add 50uL of arginase substrate (L-arginine 0.5mol/L. pH 9.7) at 37oC for 
1 hr.  Reaction stopped by adding 200uL of acid solution (H2SO4:H3PO4:H2O 
1:3:7).  For calorimetric determination of urea, α-
           ropiophenone (25uL, 9% in EtOH) was added to the 
mixture and heated to 100oC for 45 min.  After placing samples in dark for 10 
min at RT the urea concentration was determined by spectrophotometry by 
the absorbance at 550nm.  Urea production was normalized with protein 
concentration. 
Carotid Body Histology.  Carotid bifurcations were dissected, fixed for 2 
hours with 4% paraformaldehyde (Santa Cruz) and cryopreserved with 30% 
sucrose in PBS. 10 um-thick cryosections were obtained (Bright cryostat) and 
tyrosine hydroxylase (TH) positive cells were detected by 
immunofluorescence using rabbit anti-TH antibody (Novus bioscience ref: 
300-109) and goat anti-rabbit Alexa568 antibody (Life technologies ref: 
A11036). Carotid body volume and cell numbers were quantified on 
microscope images (Leica DM-RB) using ImageJ software. 
Whole Body Unrestrained Plethysmography. A single chamber 
plethysmograph (Data Science) was used in conjunction with a pressure 
transducer.  This utilises the barometric analysis technique that compares the 
pressure difference between the animal chamber and a reference chamber to 
measure airway physiological parameters.  Unanesthetized mice were 
randomly placed into the plethysmograph and allowed to acclimate.  Baseline 
averages of breathing frequency, tidal volume, inspiration and expiration 
volumes/ times were recorded.  Once acclimated to the chamber, the 
composition of the flow gas was switched from 21% O2 to 10% O2 using a 
PEGAS mixer (Columbus instruments).  The mice were housed in the 
reduced oxygen environment for 60 min before being returned to atmospheric 
oxygen. 
Oxygen Saturations.  According to the manufacturers instructions, the 
measurement was done using MouseOx® Pulse Oximeter (Starr Life 
Sciences Corp). 
Exhaled Nitric Oxide analysis 
Exhaled nitric oxide was measured non-invasively in non-anesthetised mice 
using a closed chamber system. Briefly, gas phase NO was measured by a 
chemiluminescence-based NO analyser sensitive to 0.1ppb NO (NOA 280i 
Sievers, Boulder CO).  For measurement of exhaled NO a single mouse was 
placed in a plexiglass chamber (300ml volume) and perfused with medical air 
(FIO2=21%) at a flow of 200ml/min giving a final NOA280i cell pressure of 
8Torr (8 mmHg).  Exhaled NO was continuously recorded for 15 min. Analysis 
of the final 5min was used to determine the level of exhaled NO (ppb).  
Measurement of exhaled NO from chronic hypoxic mice followed the same 
protocol as above except the carrier gas was mixed for FIO2=10%. 
Whole Lung Nitric Oxide analysis 
Lung nitrogen oxides (NOx) were isolated from 100 mg of homogenized tissue 
using a hypotonic lysis buffer and were centrifuged at 1,000 × g, 4 °C, for 5 
min. All samples were analyzed for total NOx content using an NOA 280i 
(Siever, GE Healthcare) according to the manufacturer’s instructions. 
Primary Lung endothelial cell isolation 
Primary endothelial cells were isolated and cultured from lungs of L1cre-
HIF2α and wt mice. Briefly, the lungs were excised, minced, and digested for 
90 min at 37°C in 2 mg/ml collagenase type I (Roche) in HBSS containing 
2 mM CaCl2, 2 mM MgSO4, and 20 mM HEPES. The digest was filtered 
through a 70 μm nylon cell strainer and washed once in HBSS. Pellet was 
then resuspended in PBS containing 0.1% BSA and incubated with anti-
CD31-coated magnetic beads (Dynal, Invitrogen) for 1 hr at 4°C. Separated 
cells and beads were plated in endothelial cell growth medium (ECGM) 
consisting of low glucose DMEM:F12 with 1% penicillin/streptomycin, 1% 
nonessential aminoacids, 2 mM sodium pyruvate, buffered with 20 mM 
HEPES and containing 20% FBS (Omega Scientific, Tarzana, CA), 20 μg/ml 
Heparin (Sigma, St. Louis, MO), and 75 μg/ml endothelial mitogens 
(Biomedical Technologies).  
Knockdown experiments. 
Human blood outgrowth endothelial cells derived from both control and PAH 
donors were transduced using lentiviral particles containing three different 
short hairpin RNAs (shRNAs) targeting human HIF-1α, HIF-2α, and Arg-2 
mRNA, respectively. shRNA sequences were selected from The RNAi 
Consortium (TRC) according with the following criteria: those shRNAs 
appearing to have less potential off-targets binding sites and that were 
validated by MISSION® shRNA Library (Sigma-Aldrich). The individual clones 
ID selected were: TRCN0000003808 (HIF1α-1), TRCN0000003810 
(HIF1α−2), TRCN0000003811 (HIF1α-3), TRCN0000003806 (HIF2α-1), 
TRCN0000342501 (HIF2α-2), TRCN0000003805 (HIF2α-3), 
TRCN0000333446 (ARG2-1), TRCN0000369866 (ARG2-2), and 
TRCN0000363741 (ARG2-3). Oligos for each individual shRNA were 
annealed and cloned into pLKO.1 plasmid following TRC recommendations. 
Positive colonies were checked by sequencing. To produce lentiviral vectors, 
Lenti-XTM 293T cells (Clontech) were co-transfected with single pLKO.1, 
pCMV-dR8.91 and pMD2.G plasmids using Lipofectamine 2000 (Thermo-
Fisher Scientific) manufacturer’s protocol. Lentiviral particles were collected 
48 hours after transfection and used to transduce BOECs over night. Next, 
fresh media was added and the cells were incubated in normoxia for 2 day 
then in 1% O2 atmosphere for 16 hours.   
Pulmonary Vascular Morphometry.  Lung tissues were stained with 
hematoxylin and eosin, sirius red or elastic van Gieson (EVG) stain to assess 
morphology (all Merck/BDH, Lutterworth UK).  To determine the degree of 
muscularization of small pulmonary arteries, serial lung tissue sections were 
stained with anti-smooth muscle α-actin (α-SMactin; DakoCytomation Ely UK) 
and von Willebrand factor (DakoCytomation).  Antibody staining was 
visualised using 3-3’ diaminobenzidine hydrochloride substrate 
(DakoCytomation) and counterstained with Carrazzi hematoxylin (Bios 
Shelmersdale UK).  Tissue sections were independently coded by a third 
person before quantification of the sections. Vessel medial thickness was 
measured using Image J software (MediaCybernetics, Bethesda MD). 
RNA Analysis. Total RNA and DNA was isolated from the lung using TRI-
reagent (Sigma) followed by RNA clean-up and DNase digest using RNeasy 
column kits (Qiagen).  First-strand synthesis was performed with 1µg of total 
RNA using a high-capacity cDNA kit (Applied Biosystems) according to the 
manufacturers instructions.  Relative gene expression was determined by 
quantitative PCR (qPCR) (One-Step Plus Real-Time PCR System; Life 
Technologies) and was amplified in SYBR-Green master mix (Roche) and 
relevant primers from Qiagen.  Relative gene-expression levels were related 
to β-actin and B2M using the 2∆∆CT method. 
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